REFERENCES
- He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ, Whelton PK. Major causes of death among men and women in China. N Engl J Med 2005; 353: 1124–1134
- Black HR. Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials. Clin Cornerstone 2004; 6: 53–66
- Sever P. The VALUE trial: a commentary. J Renin Angiotensin Aldosterone Syst 2004; 5: 99–101
- Robinson RF, Nahata MC, Batisky DL, Mahan JD. Pharmacologic treatment of chronic pediatric hypertension. Paediatr Drugs 2005; 7: 27–40
- Magee LA, Schick B, Donnenfeld AE, Sage SR, Conover B, Cook L, McElhatton PR, Schmidt MA, Koren G. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol 1996; 174: 823–828
- Sorensen HT, Czeizel AE, Rockenbauer M, Steffensen FH, Olsen J. The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers. Acta Obstet Gynecol Scand 2001; 80: 397–401
- Hong CU. Pediatrics4th. Korean Textbook Co, SeoulKorea 1989; 821–822
- Gluckman PD, Pinal CS. Regulation of fetal growth by the somatotrophic axis. J Nutr 2003; 133(Suppl 2)1741S–1746S
- Trujillo-Ortega ME, Mota-Rojas D, Hernandez-Gonzalez R, Velazquez-Armenta EY, Nava-Ocampo AA, Ramirez-Necoechea R, Becerril-Herrera M, Alonso-Spilsbury M. Obstetric and neonatal outcomes to recombinant porcine somatotropin administered in the last third of pregnancy to primiparous sows. J Endocrinol 2006; 189: 575–582
- Lang U, Baker RS, Braems G, Zygmunt M, Kunzel W, Clark KE. Uterine blood flow- a determinant of fetal growth. Eur J Obstet Gynecol Reprod Biol 2003; 110(Suppl 1)S55–S61
- Danielsson BR, Reiland S, Rundqvist E, Danielson M. Digital defects induced by vasodilatating agents: relationship to reduction in uteroplacental blood flow. Teratology 1989; 40: 351–358
- Horimoto M, Takeuchi K, Iijima M, Tachibana M. Reproductive and developmental toxicity studies with amlodipine in rats and rabbits [in Japanese]. Oyo Yakuri 1991; 42: 167–176
- Orisakwe OE, Chilaka KC, Afonne OJ, Obi E, Ilondu N. Evaluation of the developmental toxicity of amlodipine besylate in mice. J Health Sci 2000; 46: 42–45
- Walker JJ, Mathers A, Bjornsson S, Cameron AD, Fairlie FM. The effect of acute and chronic antihypertensive therapy on maternal and fetoplacental Doppler velocimetry. Eur J Obstet Gynecol Reprod Biol 1992; 43: 193–199
- Bayliss H, Churchill D, Beevers M, Beevers DG. Anti-hypertensive drugs in pregnancy and fetal growth: evidence for “pharmacological programming” in the first trimester?. Hypertens Pregnancy 2002; 21: 161–174
- Easterling TR, Carr DB, Brateng D, Diederichs C, Schmucker B. Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 2001; 98: 427–433
- Wilcox AJ, Baird DD, Weinberg CR. Time of implantation of the conceptus and loss of pregnancy. N Engl J Med 1999; 340: 1796–1799
- Hogge WA, Byrnes AL, Lanasa MC, Surti U. The clinical use of karyotyping spontaneous abortions. Am J Obstet Gynecol 2003; 189: 397–402
- Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354(23)2443–2451